← Human Trials & Peer-Reviewed Studies
Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study
Plain-language guide to PMID 27209465 (2016): double-blind randomized controlled trial study of Somatostatin and Pasireotide in 162 patients.
Key Facts
- PMID
- 27209465
- Journal
- Endocrine
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Findling JW et al. (8 authors)
- DOI
- 10.1007/s12020-016-0978-6
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Somatostatin and Pasireotide.
LNSC assessment was an exploratory objective based on a single, optional measurement at midnight ± 1 h on the same day as one of the 24-h urinary free cortisol (UFC) measurements.
Why It Was Studied
Measuring salivary cortisol is a simple, convenient and accurate technique with potential value in monitoring patients with hypercortisolism.
Who Took Part
The study group was 162 patients.
PubMed indexes the participants as adults, both men and women.
Of 162 enrolled patients, baseline LNSC was measured in 93.
How the Study Was Run
The researchers set it up as a randomized, double-blind and multicenter study.
The patients were allocated by chance, so the Somatostatin group and the comparison group should start out alike.
As a double-blind Somatostatin study, the assignments were hidden from both participants and investigators until the end.
More than one site took part, so the patients came from several places.
What Was Measured
Measuring salivary cortisol is a simple, convenient and accurate technique with potential value in monitoring patients with hypercortisolism.
PubMed files the paper under topics including Biomarkers, Circadian Rhythm, Hydrocortisone, Hypothalamo-Hypophyseal System, Pituitary ACTH Hypersecretion, Pituitary-Adrenal System and Saliva.
Author keywords: Cushing’s disease, Pasireotide, Salivary cortisol and Urinary free cortisol.
What This Means in Plain Language
The paper is a randomized, double-blind and multicenter study of Somatostatin and Pasireotide in 162 patients.
The publication is from 2016 (Endocrine), a journal based in United States.
More context: the Somatostatin compound page and the Pasireotide compound page, all human trials.
Our Notes on the Compounds
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Pasireotide: An FDA-approved multi-receptor somatostatin analog for Cushing's disease and acromegaly; high blood sugar is a common side effect.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.